Product

3-([1,4′-Bipiperidin]-1′-ylmethyl)-7-bromo-N-(1-phenylcyclopropyl)-2-[3-(trifluoromethyl)phenyl]-4-quinolinecarboxamide

CAS No.：1336960-13-4

Other grades of this product :

3-([1,4′-Bipiperidin]-1′-ylmethyl)-7-bromo-N-(1-phenylcyclopropyl)-2-[3-(trifluoromethyl)phenyl]-4-quinolinecarboxamide Basic information

Product Name:	3-([1,4′-Bipiperidin]-1′-ylmethyl)-7-bromo-N-(1-phenylcyclopropyl)-2-[3-(trifluoromethyl)phenyl]-4-quinolinecarboxamide
Synonyms:	3-([1,4′-Bipiperidin]-1′-ylmethyl)-7-bromo-N-(1-phenylcyclopropyl)-2-[3-(trifluoromethyl)phenyl]-4-quinolinecarboxamide;GSK2193874;TRPV4 antagonist GS2193874;GSK 2193874; GSK2193874;4-Quinolinecarboxamide, 3-([1,4'-bipiperidin]-1'-ylmethyl)-7-bromo-N-(1-phenylcyclopropyl)-2-[3-(trifluoromethyl)phenyl]-;GSK2193874 >=98% (HPLC)
CAS:	1336960-13-4
MF:	C37H38BrF3N4O
MW:	691.62
EINECS:
Product Categories:
Mol File:	1336960-13-4.mol

3-([1,4′-Bipiperidin]-1′-ylmethyl)-7-bromo-N-(1-phenylcyclopropyl)-2-[3-(trifluoromethyl)phenyl]-4-quinolinecarboxamide Chemical Properties

Boiling point	737.8±60.0 °C(Predicted)
density	1.43±0.1 g/cm3(Predicted)
storage temp.	room temp
solubility	DMSO: soluble10mg/mL, clear
pka	12.82±0.20(Predicted)
form	powder
color	white to beige

Safety Information

Hazard Codes	T
Risk Statements	25-36/37/38
Safety Statements	26-45
RIDADR	UN 2811 6.1 / PGIII
WGK Germany	3

MSDS Information

3-([1,4′-Bipiperidin]-1′-ylmethyl)-7-bromo-N-(1-phenylcyclopropyl)-2-[3-(trifluoromethyl)phenyl]-4-quinolinecarboxamide Usage And Synthesis

Uses	GSK 2193874 is an orally active, potent and selective TRPV4 antagonist.
Uses	GSK2193874 has been used as a transient receptor potential vanilloid 4 (TRPV4) antagonist: to study its effects on GSK101-induced colon contractions in mice to study its effects on murine compact bone-derived osteoblasts(CB-OB) to study its effects on lung injury post-lipopolysaccharide (LPS) in mice
Biochem/physiol Actions	GSK2193874 is a very potent, specific antagonist of TRPV4 ion channels (IC50 = 50 nM). Lung edema caused by high pulmonary venous pressure (PVP) is driven by TRPV4 activity. GSK2193874 blocks TRPV4-mediated calcium influx in cells expressing native and recombinant TRPV4, and inhibits vascular permeability and lung edema in isolated rodent and canine lungs subjected to high PVP. The compound also resolves pulmonary edema in murine myocardial infarction model.

3-([1,4′-Bipiperidin]-1′-ylmethyl)-7-bromo-N-(1-phenylcyclopropyl)-2-[3-(trifluoromethyl)phenyl]-4-quinolinecarboxamide Preparation Products And Raw materials

Welcome！

Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.

NO. 18 ,Wujiang Road, Wulidian Street, Jiangbei District, Chongqing
+86-23-6139-8061 +86-13650506873
danny@chemdad.com sales@chemdad.com
www.chemdad.com
WhatsApp +86-13650506873